FDA approves Beximco's generic Robaxin tablets

Bangladesh's largest drugmaker Beximco Pharmaceuticals (AIM: BXP) has received approval from the US Food and Drug Administration (FDA) for its generic version of Auxilium Pharmaceuticals' (Nasdaq: AUXL) Robaxin (methocarbamol) tablets for acute musculoskeletal conditions.

This is Beximco's fourth Abbreviated New Drug Application (ANDA) successfully approved for the US market since the company's oral solid dosage facility was approved by the FDA two years ago.

"We are delighted to have received our fourth product approval, within two years, from the FDA. I firmly believe our US product approvals to date, along with our growing pipeline, will help us to continue to build our presence in this important market," said Nazmul Hassan, managing director of Beximco.